3M Health Care (NYSE:MMM) said Tuesday it plans to keep its Health Information Systems business, which it mulled spinning-off or selling last September. 3M’s Health Information Systems business provides healthcare data aggregation, analysis and strategic services. The division develops and supports algorithms and software designed to improve clinical documentation, performance and quality monitoring and terminology management, the company […]
(Reuters) — 3M Co. (NYSE:MMM) said today that it’s exploring a sale or spinoff of its healthcare data and software business. The decision comes as CEO Inge Thulin reviews 3M’s broad business portfolio, which includes Post-it notes as well as adhesives, abrasives and other products for a variety of industries. At the same time, the company has […]
3M Co. (NYSE:MMM) said today that it paid $1 billion for the Polypore’s (NYSE:PPO) separations media business, which makes membranes and modules for blood treatment, ultrafiltration and gas transfer. St. Paul, Minn.-based 3M said Polypore’s separation media segment puts up annual sales of roughly $210 million. The acquisition is expected to dilute earnings this year by […]
Profits for the healthcare unit at 3M Co. (NYSE:MMM) rose during the 2nd quarter, despite a nearly -4% top-line slide, the industrial conglomerate said today. St. Paul, Minn.-based 3M Healthcare posted operating profits of $440 million on sales of $1.36 billion for the 3 months ended June 30, representing profit growth of 1.4% despite a […]
February 23, 2015 by Brian Johnson
3M Cos. (NYSE:MMM) announced it has entered into an agreement to buy disinfectant-products maker Ivera.
Ivera’s lead product, the Curos I.V. port-connector cap, is used to help prevent catheter-related blood-stream infections, or CRBSIs. 3M said the product will complement its Tegaderm line of antimicrobial I.V. securement dressings.
A scientific advisory panel to the EPA is convening today to evalute the environmental watchdog’s determination that a common medical device sterilizer, ethylene oxide, is carcinogenic.
If the panel confirms that assessment, medtech companies warn, it could disrupt the supply chain for their lifesaving products.
October 16, 2014 by Brian Johnson
(Reuters) – ConvaTec‘s owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.